Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
pulmonary arterial hypertension
Pharma
Merck preps filings after Winrevair succeeds in severe PAH study
Eight months after snaring a first FDA green light, Merck & Co. is bolstering the case for the chief asset in its $11.5 billion Acceleron acquisition.
Fraiser Kansteiner
Nov 25, 2024 9:00am
Merck joins ALA's pulmonary arterial hypertension awareness push
Nov 14, 2024 10:50am
FDA balks at standard nod to Liquidia's PAH rival to United med
Aug 19, 2024 11:34am
Aerovate's stock plummets after sole product fails in PAH trial
Jun 17, 2024 7:25pm
Merck aims to 'outnumber' pulmonary arterial hypertension
Apr 16, 2024 10:37am
Courts clear FDA to approve Liquidia's PAH drug Yutrepia
Apr 2, 2024 9:33am
